EMD Serono Establishes Immuno-Oncology Platform

EMD Serono, Inc., a subsidiary of Merck KGaA, Darmstadt, has established a dedicated immuno-oncology innovation platform integrating research, early development and biomarker strategies. The new platform will focus on developing therapies that leverage the immune system’s natural ability to fight tumors, and work in combination with existing and future therapies.

The new immuno-oncology platform includes therapeutic cancer vaccines, cancer stem cells, and immunotolerance. The portfolio comprises candidates in early clinical development and preclinical molecules including a monoclonal antibody targeting PD-L1 (programmed cell death ligand, NHS-IL12, a cancer immunotherapy targeting IL-12 to the necrotic regions of tumors, and NHS-IL2, targeting IL-2 to the necrotic regions of tumors.

“Our goal is to develop leading immunotherapies that work in combination with other therapeutic modalities, understanding that attacking multiple cancer targets simultaneously increases the possibility of therapeutic success,” said Helen Sabzevari, head of Immuno-Oncology, Global Research and Early Development at Merck Serono, a division of Merck KGaA, Darmstadt, Germany. “We are committed to delivering on the promise of immuno-oncology by combining creative thinking with strong research and clinical excellence, and, more importantly, by keeping patient needs at the heart of our efforts.”